Dr. Sharmistha Ghosh-Janjigian serves as a Program Director for the Cancer Biomarkers Research Group (CBRG) grants portfolio and is involved in the development of various initiatives in risk assessment, detection, diagnosis and prognosis of early cancer. Her portfolio includes breast and pancreatic cancers. She is involved in the activities of the following consortia: Early Detection Research Network (EDRN); Molecular Characterization of Screen-Detected Lesions (MCL) Consortium; Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer (CPDPC) (with National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK]); and Pancreatic Cancer Detection Consortium (PCDC). She provides programmatic leadership to the PCDC, which conducts research on the discovery/development of new molecular and imaging biomarkers to improve the detection of early stage pancreatic ductal adenocarcinoma and identify patients who could be candidates for early intervention. Dr. Ghosh-Janjigian also led the evaluation of the Early Detection Research Network (EDRN) Program in 2013. She has served as the CBRG and/or divisional representative for many trans-divisional activities/initiatives.
She earned her undergraduate and graduate degrees from Presidency College, University of Calcutta, and Jawaharlal Nehru University in India, and conducted postgraduate research at the Beth Israel Deaconess Medical Center/Harvard Medical School in Boston. Her research background in molecular biology and immunology includes transcription factor mapping and study of morphogenetic pathways and virulence in Candida albicans, regulated secretion of clinical biomarker ferritin, study of cannabinoids, immune system and breast cancer, and DNA vaccine studies. Prior to joining the Division, Dr. Ghosh-Janjigian served as a Scientific Editor for Biochimica et Biophysica Acta and a Senior Editor for Journal of the National Cancer Institute.